Literature DB >> 21247981

Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody.

Paul Sanders1, Stuart Young, Jane Sanders, Katarzyna Kabelis, Stuart Baker, Andrew Sullivan, Michele Evans, Jill Clark, Jane Wilmot, Xiaoling Hu, Emma Roberts, Michael Powell, Ricardo Núñez Miguel, Jadwiga Furmaniak, Bernard Rees Smith.   

Abstract

A complex of the TSH receptor extracellular domain (amino acids 22-260; TSHR260) bound to a blocking-type human monoclonal autoantibody (K1-70) was purified, crystallised and the structure solved at 1.9 Å resolution. K1-70 Fab binds to the concave surface of the TSHR leucine-rich domain (LRD) forming a large interface (2565 Å(2)) with an extensive network of ionic, polar and hydrophobic interactions. Mutation of TSHR or K1-70 residues showing strong interactions in the solved structure influenced the activity of K1-70, indicating that the binding detail observed in the complex reflects interactions of K1-70 with intact, functionally active TSHR. Unbound K1-70 Fab was prepared and crystallised to 2.22 Å resolution. Virtually no movement was observed in the atoms of K1-70 residues on the binding interface compared with unbound K1-70, consistent with 'lock and key' binding. The binding arrangements in the TSHR260-K1-70 Fab complex are similar to previously observed for the TSHR260-M22 Fab complex; however, K1-70 clasps the concave surface of the TSHR LRD in approximately the opposite orientation (rotated 155°) to M22. The blocking autoantibody K1-70 binds more N-terminally on the TSHR concave surface than either the stimulating autoantibody M22 or the hormone TSH, and this may reflect its different functional activity. The structure of TSHR260 in the TSHR260-K1-70 and TSHR260-M22 complexes show a root mean square deviation on all C(α) atoms of only 0.51 Å. These high-resolution crystal structures provide a foundation for developing new strategies to understand and control TSHR activation and the autoimmune response to the TSHR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21247981     DOI: 10.1530/JME-10-0127

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  57 in total

1.  Insight into thyroid-stimulating autoantibody interaction with the thyrotropin receptor N-terminus based on mutagenesis and re-evaluation of ambiguity in this region of the receptor crystal structure.

Authors:  Sepehr Hamidi; Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2011-08-11       Impact factor: 6.568

2.  The Activation Mechanism of Glycoprotein Hormone Receptors with Implications in the Cause and Therapy of Endocrine Diseases.

Authors:  Antje Brüser; Angela Schulz; Sven Rothemund; Albert Ricken; Davide Calebiro; Gunnar Kleinau; Torsten Schöneberg
Journal:  J Biol Chem       Date:  2015-11-18       Impact factor: 5.157

Review 3.  Autoantibodies as Endogenous Modulators of GPCR Signaling.

Authors:  Meredith A Skiba; Andrew C Kruse
Journal:  Trends Pharmacol Sci       Date:  2020-12-24       Impact factor: 14.819

Review 4.  TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.

Authors:  Terry J Smith
Journal:  Nat Rev Endocrinol       Date:  2015-01-06       Impact factor: 43.330

5.  Structure of a Thyrotropin Receptor Monoclonal Antibody Variable Region Provides Insight into Potential Mechanisms for its Inverse Agonist Activity.

Authors:  Chun-Rong Chen; Sandra M McLachlan; Paul A Hubbard; Randall McNally; Ramachandran Murali; Basil Rapoport
Journal:  Thyroid       Date:  2018-06-29       Impact factor: 6.568

Review 6.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

Review 7.  Delineating the autoimmune mechanisms in Graves' disease.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 8.  Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.

Authors:  Terry F Davies; Rauf Latif
Journal:  Expert Opin Ther Targets       Date:  2015-03-13       Impact factor: 6.902

9.  Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease.

Authors:  T Diana; J Krause; P D Olivo; J König; M Kanitz; B Decallonne; G J Kahaly
Journal:  Clin Exp Immunol       Date:  2017-05-16       Impact factor: 4.330

Review 10.  TSH Receptor Cleavage Into Subunits and Shedding of the A-Subunit; A Molecular and Clinical Perspective.

Authors:  Basil Rapoport; Sandra M McLachlan
Journal:  Endocr Rev       Date:  2016-02       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.